Novel targeted therapies in chordoma: An update

Salvatore Di Maio, Stephen Yip, Gmaan A. Al Zhrani, Fahad E. Alotaibi, Abdulrahman Al Turki, Esther Kong, Robert C. Rostomily

Research output: Contribution to journalReview article

42 Scopus citations

Abstract

Chordomas are rare, locally aggressive skull base neoplasms known for local recurrence and not-infrequent treatment failure. Current evidence supports the role of maximal safe surgical resection. In addition to open skull-base approaches, the endoscopic endonasal approach to clival chordomas has been reported with favorable albeit early results. Adjuvant radiation is prescribed following complete resection, alternatively for gross residual disease or at the time of recurrence. The modalities of adjuvant radiation therapy reported vary widely and include proton-beam, carbon-ion, fractionated photon radiotherapy, and photon and gamma-knife radiosurgery. As of now, no direct comparison is available, and high-level evidence demonstrating superiority of one modality over another is lacking. While systemic therapies have yet to form part of any first-line therapy for chordomas, a number of targeted agents have been evaluated to date that inhibit specific molecules and their respective pathways known to be implicated in chordomas. These include EGFR (erlotinib, gefitinib, lapatinib), PDGFR (imatinib), mTOR (rapamycin), and VEGF (bevacizumab). This article provides an update of the current multimodality treatment of cranial base chordomas, with an emphasis on how current understanding of molecular pathogenesis provides a framework for the development of novel targeted approaches.

Original languageEnglish (US)
Pages (from-to)873-883
Number of pages11
JournalTherapeutics and Clinical Risk Management
Volume11
DOIs
StatePublished - May 26 2015

Keywords

  • Cell lines
  • Chordomas
  • Molecular genetics
  • Radiation therapy
  • Skull-base neoplasms
  • Surgery

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Fingerprint Dive into the research topics of 'Novel targeted therapies in chordoma: An update'. Together they form a unique fingerprint.

Cite this